Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $40,541 | 3 | 76.7% |
| Travel and Lodging | $12,139 | 7 | 23.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $85.00 | 1 | 0.2% |
| Food and Beverage | $55.51 | 2 | 0.1% |
| Education | $8.68 | 2 | 0.0% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $51,335 | 10 | $0 (2023) |
| Janssen Research & Development, LLC | $1,400 | 2 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $85.00 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $13,595 | 11 | Eli Lilly and Company ($12,195) |
| 2021 | $39,141 | 1 | Eli Lilly and Company ($39,141) |
| 2019 | $4.74 | 1 | Retrophin, Inc. ($4.74) |
| 2018 | $85.00 | 1 | Takeda Pharmaceuticals U.S.A., Inc. ($85.00) |
| 2017 | $3.94 | 1 | Retrophin, Inc. ($3.94) |
All Payment Transactions
15 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2023 | Eli Lilly and Company | — | Travel and Lodging | Cash or cash equivalent | $619.11 | General |
| 12/13/2023 | Eli Lilly and Company | — | Travel and Lodging | Cash or cash equivalent | $144.00 | General |
| 12/13/2023 | Eli Lilly and Company | — | Food and Beverage | Cash or cash equivalent | $47.02 | General |
| 12/13/2023 | Eli Lilly and Company | — | Food and Beverage | Cash or cash equivalent | $8.49 | General |
| 10/15/2023 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $9,899.55 | General |
| 10/15/2023 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $218.03 | General |
| 10/15/2023 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $200.48 | General |
| 05/08/2023 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $631.62 | General |
| 05/08/2023 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $426.32 | General |
| 04/30/2023 | Janssen Research & Development, LLC | STELARA (Biological) | — | Cash or cash equivalent | $1,300.00 | Research |
| Study: CNTO1275CRD3010 • Category: Immunology | ||||||
| 04/30/2023 | Janssen Research & Development, LLC | STELARA (Biological) | — | Cash or cash equivalent | $100.00 | Research |
| Study: CNTO1275CRD3010 • Category: Immunology | ||||||
| 04/01/2021 | Eli Lilly and Company | — | — | Cash or cash equivalent | $39,140.70 | Research |
| Study: MULTICENTER, OPEN-LABEL PK STUDY OF MIRIKIZUMAB IN PEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | ||||||
| 01/24/2019 | Retrophin, Inc. | (820) Cholbam (Drug) | Education | In-kind items and services | $4.74 | General |
| Category: Hepatology | ||||||
| 08/02/2018 | Takeda Pharmaceuticals U.S.A., Inc. | Entyvio (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $85.00 | General |
| Category: Lower GI | ||||||
| 05/30/2017 | Retrophin, Inc. | (820) Cholbam (Drug) | Education | In-kind items and services | $3.94 | General |
| Category: Hepatology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| MULTICENTER, OPEN-LABEL PK STUDY OF MIRIKIZUMAB IN PEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | Eli Lilly and Company | $39,141 | 1 |
| CNTO1275CRD3010 | Janssen Research & Development, LLC | $1,400 | 2 |
About Dr. Jess Kaplan, MD
Dr. Jess Kaplan, MD is a Pediatrics healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/01/2007. The National Provider Identifier (NPI) number assigned to this provider is 1205038247.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jess Kaplan, MD has received a total of $52,829 in payments from pharmaceutical and medical device companies, with $13,595 received in 2023. These payments were reported across 15 transactions from 4 companies. The most common payment nature is "" ($40,541).
Practice Information
- Specialty Pediatrics
- Location Boston, MA
- Active Since 06/01/2007
- Last Updated 11/06/2012
- Taxonomy Code 208000000X
- Entity Type Individual
- NPI Number 1205038247
Products in Payments
- STELARA (Biological) $1,400
- Entyvio (Biological) $85.00
- (820) Cholbam (Drug) $8.68
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatrics Doctors in Boston
Dr. R Ezekowitz, Mbch Dphl, MBCH DPHL
Pediatrics — Payments: $1.2M
Stephen Pelton, Md, MD
Pediatrics — Payments: $456,322
Tanya Laidlaw, M.d, M.D
Pediatrics — Payments: $307,922
Dr. Harald Jueppner, Md, MD
Pediatrics — Payments: $202,618
Rachael Grace, Md, MD
Pediatrics — Payments: $175,958
Dr. Thomas Kinane, Md, MD
Pediatrics — Payments: $175,709